Companies
Basic Pharma
produces tag-free recombinant human serum albumin (rHSA) expressed in Hansenula polymorpha yeast, in collaboration with ARTES Biotechnology (Langenfeld, Germany) — the joint product launched at BIO-Europe (October 30, 2024);…
- Country
- Netherlands
BIO-Europe joint launch with ARTES Biotechnology Oct 30, 2024; Benelux locally-anchored supply
eu
Coverage
| CN | EU | IN | US | |
|---|---|---|---|---|
| specialty-fine-chem | ✓ | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Funding | Acquisition funding round by SHS Capital on July 14, 2026 | basicpharma.nl |
| Capacity | Bioreactor capacity up to 50 L for small and pilot scale fermentation | basicpharma.nl |
| Certification | ISO 13485:2016 certified and GMP-compliant facility | basicpharma.nl · bio-connect.nl |
| Production site | Geleen, the Netherlands | basicpharma.nl · bio-connect.nl |
| Headcount | More than 100 employees; reported as 101 employees | basicpharma.nl |
Independent sources: bio-connect.nl
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Recombinant human serum albumin (rHSA) | specialty-fine-chem | Low | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.